Skip to main content

Inavolisib Dosage

Medically reviewed by Drugs.com. Last updated on Jan 28, 2025.

Applies to the following strengths: 9 mg; 3 mg

Usual Adult Dose for Breast Cancer

9 mg orally once a day, in combination with palbociclib and fulvestrant
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: In combination with palbociclib and fulvestrant, for the treatment of endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy

Renal Dose Adjustments

Mild renal dysfunction (estimated GFR 60 to less than 90 mL/min): No adjustment recommended.
Moderate renal dysfunction (estimated GFR 30 to less than 60 mL/min): Recommended initial dose is 6 mg orally once a day.
Severe renal dysfunction (estimated GFR less than 30 mL/min): Data not available; population not studied.

Liver Dose Adjustments

Liver dysfunction: Data not available

Comments:

Dose Adjustments

General Dose Reduction Recommendations:


Dosage Modifications for Adverse Reactions:
HYPERGLYCEMIA:
Fasting plasma or blood glucose levels greater than the upper limit of normal to 160 mg/dL (8.9 mmol/L):

Fasting plasma or blood glucose levels greater than 160 to 250 mg/dL (8.9 to 13.9 mmol/L):

Fasting plasma or blood glucose levels greater than 250 to 500 mg/dL (13.9 to 27.8 mmol/L):

Fasting plasma or blood glucose levels greater than 500 mg/dL (27.8 mmol/L):

STOMATITIS:

DIARRHEA:

HEMATOLOGIC TOXICITIES:

OTHER ADVERSE REACTIONS:

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

General:

Monitoring:

Patient advice:

More about inavolisib

Patient resources

Other brands

Itovebi

Professional resources

Other brands

Itovebi

Related treatment guides

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.